Real World Evidence Solutions Market

Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2028

Report ID: MRHC - 104253
Pages: 214
Dec-2021
Formats*: PDF
Category: Healthcare
Delivery: 2 to 4 Hours

COVID-19

This report provides pre & post COVID-19 market estimates.

The RWE Solutions Market is expected to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028. Real-world evidence (RWE) is clinical evidence gathered via Real-Word data (RWD) analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are expected to positively impact the RWE solutions market.

Impact of COVID-19 on RWE Solutions Market

The key players operating in the RWE solutions market experienced an initial market shrinkage due to uncertainties associated with the impact of the COVID-19 pandemic. The market shrinkage was mainly due to significant restrictions on travel in many countries, shifting of resources on COVID-19 treatments in healthcare settings, and limited access to hospitals.

However, after the initial market shrinkage, real-world evidence (RWE) is set to become the most influential emerging technology to combat the COVID-19 outbreak.

Healthcare professionals are working tirelessly on faster diagnosis, rapid response, and effective use of human resources and ensuring the safety of medical personnel all over the globe. As the COVID-19 outbreak continues to take its toll on global markets, real-world evidence (RWE) is set to become the most influential emerging technology to combat the COVID-19 outbreak. Real-world evidence is becoming an essential tool in trying to suppress COVID-19. There are growing interests in whether non-randomized real-world evidence (RWE) can be used to supplement RCT evidence and aid in clinical decision-making, but concerns about non-randomized RWE have been highlighted by a proliferation of RWE studies on medications and COVID-19 outcomes with widely varying conclusions. A systematic approach to generating information to support clinical and public health decision-making is needed. Real-world data (RWD) captured directly from patients or through medical claims or electronic medical records (EMRs), has the potential to support clinical decision-making.

Real World Evidence Solutions Market

Click here to: Get Free Request Sample Copy of this report

Key Findings in the Global RWE Solutions Market Study

Datasets Generated Larger Proportion of Revenue Compared to Consulting Services

The datasets segment is estimated to account for a larger share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Market Access & Reimbursement/ Coverage Decisions to Dominate the Market

The market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing demand for real-world data and real-world evidence for accelerating market access & reimbursement/coverage decisions, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).

Pharmaceutical, Biotechnology, & Medical Device Companies Segment to Register Largest Share in the RWE solutions market by 2028

The pharmaceutical, biotechnology, & medical device companies segment is estimated to account for the largest share of the RWE solutions market in 2021. The large market share of this segment is mainly attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

Asia-Pacific: Fastest Growing Regional Market

North America is estimated to command the largest share of the global RWE solutions market in 2021, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa.

However, Asia-Pacific is expected to be the fastest-growing regional market due to growing demand from payers for data that defines the value and effectiveness of medicines, growing demand in conducting real-world studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years. The key players profiled in the global RWE solutions market report includes IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.) , CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report

RWE Solutions Market, by Component

Datasets
- Disparate Datasets
  - EMR/EHR/Clinical Data
  - Claims & Billing Data
  - Pharmacy Data
  - Product/Disease Registries Data
  - Other Disparate Datasets
- Integrated Datasets
Consulting & Analytics

(Note: Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

RWE Solutions Market, by Application

Market Access & Reimbursement/Coverage Decisions
Drug Development & Approvals
- Oncology
- Neurology
- Immunology
- Cardiovascular Diseases
- Other Therapeutic Areas
Post Market Surveillance
Medical Device Development & Approvals
Other Applications
(Note: Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases, Other Applications include regulatory and clinical decision-making)

RWE Solutions Market, by End User

Pharmaceutical, Biotechnology, and Medical Device Companies
Healthcare Payers
Healthcare Providers
Other End Users
(Note: Other end-users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

RWE Solutions Market, by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- Japan
- China
- India
- South Korea
- Taiwan
- Singapore
- Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Key questions answered in the report:

What is the focus of the global RWE solutions market?

The global RWE solutions market covers the market sizes & forecasts the various real-world evidence solutions offered by key market players to support pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to market access and reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals. The RWE solutions market studied in this report involves the value analysis of various segments and subsegments of RWE solutions providers at the regional and country levels.

What is the value of revenue generated from the RWE solutions across the globe? at what rate is their demand expected to grow for the next 5–7 years?

The global RWE solutions market is projected to reach $4.4 billion by 2028, at a CAGR of 11.8% during the forecast period.

Which component type is estimated to hold the major share of the market?

Based on component, the datasets segment is estimated to account for the largest share of the RWE solutions market in 2020. The large market share of this segment is mainly attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Which application segment of the market is projected to create more traction in the RWE solutions market?

The drug development & approvals segment is estimated to register the fastest CAGR during the forecast period due to increasing demand for real-world data and real-world evidence for accelerating drug discovery and development, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).

What are the key factors supporting the growth of this market? also, what are the major opportunities for existing market players and new entrants in the global RWE solutions market?

Growing incidence of chronic diseases, delays in drug development, and the subsequent increase in development costs, rapidly growing big data in healthcare, shift from volume to value-based care, and the rising focus towards personalized healthcare are expected to positively impact the growth of the RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to-end RWE services, and the rising adoption of wearable devices and AI in RWE.

Who are the major players operating in the global RWE solutions market?

Key companies operating in the global RWE solutions market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Which regions/countries are expected to offer significant growth opportunities for the companies operating in the RWE solutions market?

Emerging economies from the Asian region such as Japan and China are projected to offer significant growth opportunities for the companies in operating this market. The growing demand from payers for data that defines the value and effectiveness of medicines, growing demand in conducting real-world studies in drug R&D, and the increasing government interest in using real-world studies for regulatory decision-making are the factors expected to offer significant growth opportunities in this region.

Download Sample

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Growing Burden of Chronic Diseases
4.2.2. Rising Focus Towards Personalized Healthcare
4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
4.2.4. Shift Towards Value-Based Care
4.2.5. Rapidly Growing Big Data in Healthcare
4.3. Restraints
4.3.1. Reluctance to Rely on Real-World Studies
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Rising Focus on End-To-End RWE Services
4.4.3. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
4.5. Challenges
4.5.1. Lack of Standardized Methodologies to Develop RWE
4.6. Impact Assessment of COVID-19
4.7. Key Market Trends
4.7.1. Growing Adoption of RWE in Drug Development and Commercialization
4.7.2. Rising Number of Consolidations
4.7.3. Improved Patient Outcomes and value Creation from real world Evidence

5. Regulatory Analysis – Real-World Evidence (RWE) Solutions Market
5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. Rest of the World

6. Pricing Models (Emr/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-Based Pricing)
6.3. Pay Per Usage (Value-Based Pricing)
6.4. Annual Subscription

7. Global Real-World Evidence Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Product/Disease Registries Data
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting & Analytics

8. Global Real-World Evidence Solutions Market, by Application
8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decisions
8.3. Drug Development & Approvals
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Immunology
8.3.4. Cardiovascular Diseases
8.3.5. Other Therapeutic Areas
8.4. Post Market Surveillance
8.5. Medical Device Development & Approvals
8.6. Other Applications

9. Global Real-World Evidence Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users

10. Global Real-World Evidence Solutions Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. South Korea
10.4.5. Taiwan
10.4.6. Singapore
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa

11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2020)
11.4.1. IQVIA Holdings, Inc. (U.S.)
11.4.2. Icon Plc (Ireland)
11.4.3. PPD, Inc.

12. Company Profiles
12.1. IQVIA Holdings Inc.
12.1.1. Business Overview
12.1.2. Financial Overview
12.1.3. Product Portfolio
12.1.4. Strategic Developments
12.2. PPD, Inc.
12.2.1. Business Overview
12.2.2. Financial Overview
12.2.3. Product Portfolio
12.2.4. Strategic Developments
12.3. ICON plc
12.3.1. Business Overview
12.3.2. Financial Overview
12.3.3. Product Portfolio
12.3.4. Strategic Developments
12.4. SYNEOS HEALTH, INC.
12.4.1. Business Overview
12.4.2. Financial Overview
12.4.3. Product Portfolio
12.4.4. Strategic Developments
12.5. CLARIVATE PLC
12.5.1. Business Overview
12.5.2. Financial Overview
12.5.3. Product Portfolio
12.6. Medpace Holdings Inc.
12.6.1. Business Overview
12.6.2. Financial Overview
12.6.3. Product Portfolio
12.7. Symphony Innovation, LLC
12.7.1. Business Overview
12.7.2. Product Portfolio
12.7.3. Strategic Developments
12.8. PAREXEL International Corporation
12.8.1. Business Overview
12.8.2. Product Portfolio
12.8.3. Strategic Developments
12.9. IBM Corporation
12.9.1. Business Overview
12.9.2. Financial Overview
12.9.3. Product Portfolio
12.9.4. Strategic Developments
12.10. UnitedHealth Group Incorporated
12.10.1. Business Overview
12.10.2. Financial Overview
12.10.3. Product Portfolio
12.11. Flatiron Health
12.11.1. Business Overview
12.11.2. Product Portfolio
12.11.3. Strategic Developments
12.12. Oracle Corporation
12.12.1. Business Overview
12.12.2. Financial Overview
12.12.3. Product Portfolio
12.13. SAS Institute, Inc.
12.13.1. Business Overview
12.13.2. Product Portfolio
12.13.2. Strategic Developments
12.14. Clinigen Group plc
12.14.1. Business Overview
12.14.2. Financial Overview
12.14.3. Product Portfolio
12.15. Cognizant Technology Solutions Corporation
12.15.1. Business Overview
12.15.2. Financial Overview
12.15.3. Product Portfolio
12.16. PerkinElmer, Inc.
12.16.1. Business Overview
12.16.2. Financial Overview
12.16.3. Product Portfolio

13. Appendix
13.1. Questionnaire
13.2. Available Customization

List of Tables

Table 1 Global Real-World Evidencesolutions Market Drivers: Impact Analysis (2021-2028)
Table 2 Number of Persons Aged 65 Years or Over, by Region, (2019 Vs. 2050)
Table 3 Total Per-Study Cost (In USD Million), by Phase and Therapeutic Area
Table 4 Sources of Healthcare Data
Table 5 Global Real-World Evidence Solutions Market Restraints: Impact Analysis (2021-2028)
Table 6 RWE in Latin American Countries
Table 7 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
Table 8 Global Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 9 Global Real-World Evidence Solutions Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 10 Real-World Evidence Solutions Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 11 Global RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 12 RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 13 RWE Emr/Ehr/Clinical Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 14 RWE Claims & Billing Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 15 RWE Pharmacy Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 16 RWE Product/Disease Registries Data Market Size, by Country/Region, 2019–2028 (USD Million)
Table 17 Other RWE Disparate Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 18 RWE Integrated Datasets Market Size, by Country/Region, 2019–2028 (USD Million)
Table 19 RWE Consulting & Analytics Market Size, by Country/Region, 2019–2028 (USD Million)
Table 20 Global Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 21 Global RWE Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2019–2028 (USD Million)
Table 22 Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 23 Global RWE Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 24 Oncology: Drugs in the R&D Pipeline
Table 25 Global RWE Solutions Market Size for Oncology, by Country/Region, 2019–2028 (USD Million)
Table 26 Neurology: Drugs in the R&D Pipeline
Table 27 Global RWE Solutions Market Size for Neurology, by Country/Region, 2019–2028 (USD Million)
Table 28 Immunology: Drugs in the R&D Pipeline
Table 29 Global RWE Solutions Market Size for Immunology, by Country/Region, 2019–2028 (USD Million)
Table 30 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
Table 31 Cardiovascular Diseases: Drugs in the R&D Pipeline
Table 32 Global RWE Solutions Market Size for Cardiovascular Diseases, by Country/Region, 2019–2028 (USD Million)
Table 33 Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 34 Global RWE Solutions Market Size for Other Therapeutic Areas, by Country/Region, 2019–2028 (USD Million)
Table 35 Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2028 (USD Million)
Table 36 Global RWE Solutions Market Size for Post-Market Surveillance, by Country/ Region, 2019–2028 (USD Million)
Table 37 Global RWE Solutions Market Size for Other Applications, by Country/Region, 2019–2028 (USD Million)
Table 38 Global RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 39 Global RWE Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2019–2028 (USD Million)
Table 40 Global RWE Solutions Market Size for Healthcare Payers, by Country/Region, 2019–2028 (USD Million)
Table 41 Global RWE Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2028 (USD Million)
Table 42 Global RWE Solutions Market Size for Other End Users, by Country/Region, 2019–2028 (USD Million)
Table 43 Global Real-World Evidence Solutions Market, by Country/Region, 2019–2028 (USD Million)
Table 44 North America: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 45 North America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 46 North America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 47 North America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 48 North America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 49 North America: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 50 North America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 51 U.S.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 52 U.S.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 53 U.S.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 54 U.S.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 55 U.S.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 56 U.S.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 57 Number of Active Clinical Trials in Canada, by Condition, 2019
Table 58 Canada: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 59 Canada: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 60 Canada: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 61 Canada: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 62 Canada: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 63 Canada: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 64 Europe: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 65 Europe: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 66 Europe: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 67 Europe: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 68 Europe: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 69 Europe: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 70 Europe: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 71 U.K.: Conferences and Workshops on Real-World Evidence Solutions
Table 72 U.K.: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 73 U.K.: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 74 U.K.: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 75 U.K.: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 76 U.K.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 77 U.K.: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 78 Conferences, Symposia, and Workshops in Germany
Table 79 Germany: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 80 Germany: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 81 Germany: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 82 Germany: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 83 Germany: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 84 Germany: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 85 France: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 86 France: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 87 France: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 88 France: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 89 France: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 90 France: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 91 Italy: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 92 Italy: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 93 Italy: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 94 Italy: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 95 Italy: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 96 Italy: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 97 Spain: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 98 Spain: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 99 Spain: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 100 Spain: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 101 Spain: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 102 Spain: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 103 RoE: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 104 RoE: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 105 RoE: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 106 RoE: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 107 RoE: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 108 RoE: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 109 Asia-Pacific: Real-World Evidence Solutions Market Size, by Country, 2019–2028 (USD Million)
Table 110 Asia-Pacific: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 111 Asia-Pacific: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 112 Asia-Pacific: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 113 Asia-Pacific: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 114 Asia-Pacific: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 115 Asia-Pacific: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 116 Japan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 117 Japan: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 118 Japan: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 119 Japan: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 120 Japan: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 121 Japan: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 122 Diversified Real-World Data Sources in China
Table 123 China: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 124 China: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 125 China: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 126 China: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 127 China: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 128 China: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 135 South Korea: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 141 RWE Sources Of Taiwan
Table 142 Taiwan: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 148 Singapore: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 154 Estimated Number of New Cancer Cases From 2020 to 2030
Table 155 RoAPAC: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 156 RoAPAC: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 157 RoAPAC: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 158 RoAPAC: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 159 RoAPAC: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 160 RoAPAC: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 161 Latin America: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 162 Latin America: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 163 Latin America: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 164 Latin America: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 165 Latin America: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 166 Latin America: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 167 Middle East & Africa: Real-World Evidence Solutions Market Size, by Component, 2019–2028 (USD Million)
Table 168 Middle East & Africa: RWE Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 169 Middle East & Africa: RWE Disparate Datasets Market Size, by Type, 2019–2028 (USD Million)
Table 170 Middle East & Africa: Real-World Evidence Solutions Market Size, by Application, 2019–2028 (USD Million)
Table 171 Middle East & Africa: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2019–2028 (USD Million)
Table 172 Middle East & Africa: RWE Solutions Market Size, by End User, 2019–2028 (USD Million)
Table 173 Recent Developments, by Company, 2018–2021

List of Figures

Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global Real-World Evidence Solutions Market, by Component, 2021 Vs. 2028 (USD Million)
Figure 9 Global Real-World Evidence Solutions Market, by Application, 2021 Vs. 2028 (USD Million)
Figure 10 Global Real-World Evidence Solutions Market, by End User, 2021 Vs. 2028 (USD Million)
Figure 11 Real-World Evidence Solutions Market, by Geography
Figure 12 Market Dynamics
Figure 13 Number of People With Chronic Conditions in the U.S. (2000–2030)
Figure 14 Percentage of Personalized Medicines Approved (2015–2020)
Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012–2020)
Figure 16 Global Real-World Evidence Solutions Market Size, by Component, 2021–2028 (USD Million)
Figure 17 U.S.: Number of E-Prescriptions, 2013–2020 (Billions)
Figure 18 Global Real-World Evidence Solutions Market Size, by Application, 2021–2028(USD Million)
Figure 19 Estimated Number of New Cancer Cases, by Region, 2020–2040 (in Millions)
Figure 20 Global Real-World Evidence Solutions Market Size, by End User, 2021–2028 (USD Million)
Figure 21 Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 22 Global Real-World Evidence Solutions Market, by Region, 2021–2028 (USD Million)
Figure 23 North America: Real-World Evidence Solutions Market Snapshot
Figure 24 Number of Novel Drug Approvals by CDER in a Year, 2010–2020
Figure 25 Europe: Real-World Evidence Solutions Market Snapshot
Figure 26 Pharmaceutical Industry R&D Expenditure in Germany, 2016–2019 (USD Million)
Figure 27 France: Share of Population Aged 65 & Above, 2010–2020
Figure 28 Italy: Share of Population Aged 65 Years and Above, 2015–2020
Figure 29 Pharmaceutical R&D Expenditure in Spain, 2016–2019 (USD Million)
Figure 30 Pharmaceutical R&D Expenditure in European Countries, 2016–2019 (USD Million)
Figure 31 Asia-Pacific: Real-World Evidence Solutions Market Snapshot
Figure 32 Number of People >65 Years of Age in Japan, 2000–2050
Figure 33 Key Growth Strategies Adopted by Leading Players (2018–2021)
Figure 34 Real-World Evidence Solutions: Competitive Benchmarking
Figure 35 Market Share Analysis: Real-World Evidence Solutions Industry (2020)
Figure 36 IQVIA Holdings Inc.: Financial Overview, 2020
Figure 37 PPD, Inc.: Financial Overview, 2020
Figure 38 ICON plc: Financial Overview, 2020
Figure 39 SYNEOS HEALTH, INC.: financial overview (2020)
Figure 40 CLARIVATE PLC: financial overview (2020)
Figure 41 Medpace Holdings, Inc.: financial overview, 2020
Figure 42 IBM Corporation: Financial Overview, 2020
Figure 43 UnitedHealth Group Incorporated: Financial Overview, 2020
Figure 44 Oracle Corporation: Financial Overview, 2021
Figure 45 Clinigen Group plc: Financial Overview, 2021
Figure 46 Cognizant Technology Solutions Corporation: Financial Overview, 2020
Figure 47 PerkinElmer, Inc.: Financial Overview, 2020

Download Sample

Full Name:

Name can only consist of alphabets.

Please provide your full name.

Email:

Please provide valid email address.

Please provide your email address.

Job Title:

Please provide your job title.

Company:

Please provide your company name.

Country:

Please provide your company name.

Phone Number

Please provide valid phone number.

Please provide your phone number.

Specific Interest

Please enter minimum 10 characters.

Captcha:

Please enter Captcha.

Please enter valid Captcha.

This website is secure and we do not share your personal information with any third party. Privacy Policy

SELECT PDF LICENSE

Single User 10% Discount

$ 4027.5 ~~$ 4475.00~~ With the help of Single User License, only an individual can use our report either electronically or online. The right to use of the report should be confined only to one authorized computer. Upon buying single user license, buyer must provide the names and email ids of the authorized users of this report.

Multiple Users 15% Discount

$ 5248.75 ~~$ 6175.00~~
Multi-User license permits to access the report from five authorized computers. It does not permit you to share the report with other divisions and subsidiaries of the same company. Upon buying multi-user license, buyer must provide the names and email ids of the authorized users of this report. (Recommended)

Corporate User 20% Discount

$ 6300 ~~$ 7875.00~~ With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report is prohibited without the prior permission of Meticulous Research.

Enquire

Check Discount

Request Sample

Speak to Analyst

Real World Evidence Solutions Market

Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2028

This report provides pre & post COVID-19 market estimates.

What is the focus of the global RWE solutions market?

What is the value of revenue generated from the RWE solutions across the globe? at what rate is their demand expected to grow for the next 5–7 years?

Which component type is estimated to hold the major share of the market?

Which application segment of the market is projected to create more traction in the RWE solutions market?

What are the key factors supporting the growth of this market? also, what are the major opportunities for existing market players and new entrants in the global RWE solutions market?

Who are the major players operating in the global RWE solutions market?

Which regions/countries are expected to offer significant growth opportunities for the companies operating in the RWE solutions market?

Related Research

Related Research

Grand Total

Tax